IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-03-25 (nutraingredients-asia.com)
IQVIA and NUS join forces to boost healthspan, innovate personalised health solutions
Data science company IQVIA and the National University of Singapore (NUS) are set to embark on several joint efforts to advance longevity medicine and personalised health innovations.
Read more
2025-03-18 (econovill.com)
Hanmi Pharmaceutical -Samsung Bioepis, Conclusion of Joint Sales Agreement for osteoporosis Treatment <Pharmaceutical · Bio <Industry <Article
Hanmi Pharm (CEO Park Jae -hyun) and Samsung Bioepis (CEO Kim Kyung -ah) announced on the 18th that they signed a joint sales agreement for the domestic launch of osteoporosis treatment prolia biosimilar (biopharmaceutical drug) at Hanmi Pharmaceutical Headquarters Park Hall. Samsung Bioepis is a developer of Prolia Biosimilar, which is responsible for the production and supply of products, and domestic marketing and sales activities are in charge of both companies. IQVIA
Read more
2024-01-16 (pharmavoice.com)
Pharma takes a gut check of microbiome drugs
On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.
Read more